|Dr. Nassim Usman Ph.D.||Pres, CEO & Director||769.18k||N/A||1960|
|Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D.||Consultant||577.04k||N/A||1954|
|Seline Miller||Interim Chief Financial & Principal Accounting Officer||N/A||N/A||N/A|
|Dr. Grant Blouse M.Sc., Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Ana Kapor||Sr. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Dr. Tom Knudsen D.V.M., Ph.D.||Sr. VP of Corp. Devel.||N/A||N/A||N/A|
|Mr. Charles J. Democko||Sr. VP of Regulatory Affairs & Quality||N/A||N/A||1955|
|Dr. Anju Chatterji Ph.D.||Sr. VP of Biologics Devel. & Manufacturing||N/A||N/A||N/A|
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously administered engineered coagulation; and Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. The company's pipeline also includes a preclinical program partnered with Biogen International GmbH for dry age-related macular degeneration (AMD); factor I protease for SQ prophylaxis in patients with complement factor I deficiency and C4b-degraders designed to target disorders of the classical complement pathway, as well as other complement programs. The company also develops CB 4332 intended for lifelong prophylactic SQ administration in individuals with CFI deficiency; and CB 2782-PEG, a C3 degrader product candidate in preclinical development for the treatment of dry AMD. It has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Catalyst Biosciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.